Tech Company Financing Transactions
OncoMed Pharmaceuticals Funding Round
OncoMed Pharmaceuticals secured a $40 million financing round on 6/17/2010. Investors included Bayer.
Transaction Overview
Company Name
Announced On
6/17/2010
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The deal will provide OncoMed with $40 million in upfront cash, and also could offer milestone payments for as many as five different drug candidates, which have potential to generate as much as $387 million in milestone payments each for OncoMed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
800 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
OncoMed Pharmaceuticals (NASDAQ: OMED) is discovering and developing monoclonal antibodies and small molecules capable of destroying cancer stem cells, a recently discovered type of cell believed to seed the growth of cancers and underlie cancer's ability to spread and take root in tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Lewicki
Chief Scientific Officer
Austin Gurney
Vice President
Ann Kapoun
VP - Finance
Yvonne Li
VP - General Counsel
Alicia Hager
VP - R & D
Robert Stagg
VP - Regulatory Affairs
Jill Henrich
Browse more venture capital transactions:
Prev: 6/17/2010: Format Dynamics venture capital transaction
Next: 6/17/2010: Ferrokin BioSciences venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs